Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $190.00 at JPMorgan Chase & Co.

Jazz Pharmaceuticals (NASDAQ:JAZZFree Report) had its price target boosted by JPMorgan Chase & Co. from $170.00 to $190.00 in a report issued on Friday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of a number of other research reports. Cantor Fitzgerald reiterated an overweight rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday. HC Wainwright reduced their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a buy rating on the stock in a report on Thursday, March 14th. Truist Financial restated a buy rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. UBS Group cut their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a neutral rating on the stock in a report on Friday, March 1st. Finally, Stifel Nicolaus raised their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a research note on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $195.08.

View Our Latest Research Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:JAZZ opened at $120.79 on Friday. The company has a market capitalization of $7.61 billion, a PE ratio of 19.74, a PEG ratio of 1.69 and a beta of 0.59. Jazz Pharmaceuticals has a 12-month low of $111.25 and a 12-month high of $147.98. The business has a 50 day moving average of $122.56 and a two-hundred day moving average of $124.76. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, analysts forecast that Jazz Pharmaceuticals will post 16.15 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. Captrust Financial Advisors increased its stake in Jazz Pharmaceuticals by 2.4% during the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after purchasing an additional 86 shares during the last quarter. First Republic Investment Management Inc. boosted its holdings in Jazz Pharmaceuticals by 0.7% during the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock worth $1,922,000 after buying an additional 88 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after buying an additional 100 shares in the last quarter. Utah Retirement Systems lifted its position in shares of Jazz Pharmaceuticals by 0.9% during the 4th quarter. Utah Retirement Systems now owns 10,836 shares of the specialty pharmaceutical company’s stock valued at $1,726,000 after acquiring an additional 100 shares during the last quarter. Finally, Waterfront Wealth Inc. boosted its stake in shares of Jazz Pharmaceuticals by 1.2% during the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after acquiring an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.